These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 18409056)

  • 1. Paroxetine hydrochloride controlled release POLYOX matrix tablets: screening of formulation variables using Plackett-Burman screening design.
    Jin SJ; Yoo YH; Kim MS; Kim JS; Park JS; Hwang SJ
    Arch Pharm Res; 2008 Mar; 31(3):399-405. PubMed ID: 18409056
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Naproxen-Eudragit microspheres: screening of process and formulation variables for the preparation of extended release tablets.
    Zaghloul AA; Faltinek J; Vaithiyalingam SR; Reddy IK; Khan MA
    Pharmazie; 2001 Apr; 56(4):321-4. PubMed ID: 11338673
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Formulation and optimization of floating matrix tablets of clarithromycin using simplex lattice design.
    Singh I; Saini V
    Pak J Pharm Sci; 2016 Mar; 29(2):511-9. PubMed ID: 27087096
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative study of propranolol hydrochloride release from matrix tablets with KollidonSR or hydroxy propyl methyl cellulose.
    Sahoo J; Murthy PN; Biswal S; Sahoo SK; Mahapatra AK
    AAPS PharmSciTech; 2008; 9(2):577-82. PubMed ID: 18459050
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hydrophilic matrices: application of Placket-Burman screening design to model the effect of POLYOX-carbopol blends on drug release.
    El-Malah Y; Nazzal S
    Int J Pharm; 2006 Feb; 309(1-2):163-70. PubMed ID: 16413978
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development and comparative evaluation of in vitro, in vivo properties of novel controlled release compositions of paroxetine hydrochloride hemihydrate as against Geomatrix™ platform technology.
    Khatavkar UN; Shimpi SL; Jayaram Kumar K; Deo KD
    Drug Dev Ind Pharm; 2013 Aug; 39(8):1175-86. PubMed ID: 22607046
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of solvent on retarding the release of diltiazem HCl from Polyox-based liquisolid tablets.
    Kaialy W; Bello H; Asare-Addo K; Nokhodchi A
    J Pharm Pharmacol; 2016 Nov; 68(11):1396-1402. PubMed ID: 27714817
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Formulation of sustained-release dosage form of verapamil hydrochloride by solid dispersion technique using Eudragit RLPO or Kollidon SR.
    Sahoo J; Murthy PN; Biswal S; Manik
    AAPS PharmSciTech; 2009; 10(1):27-33. PubMed ID: 19145487
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advanced formulation design of venlafaxine hydrochloride coated and triple-layer tablets containing hypromellose.
    Gohel M; Bariya SH
    Pharm Dev Technol; 2009; 14(6):650-8. PubMed ID: 19883254
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development and optimization of a novel oral controlled delivery system for tamsulosin hydrochloride using response surface methodology.
    Kim MS; Kim JS; You YH; Park HJ; Lee S; Park JS; Woo JS; Hwang SJ
    Int J Pharm; 2007 Aug; 341(1-2):97-104. PubMed ID: 17499949
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of drug solubility on polymer hydration and drug dissolution from polyethylene oxide (PEO) matrix tablets.
    Li H; Hardy RJ; Gu X
    AAPS PharmSciTech; 2008; 9(2):437-43. PubMed ID: 18431663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Formulation and characterizations of delayed release multi particulates system of indomethacin: optimization by response surface methodology.
    Nandy BC; Mazumder B
    Curr Drug Deliv; 2014; 11(1):72-86. PubMed ID: 24783236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of manufacturing process variables on in vitro dissolution characteristics of extended-release tablets formulated with hydroxypropyl methylcellulose.
    Huang Y; Khanvilkar KH; Moore AD; Hilliard-Lott M
    Drug Dev Ind Pharm; 2003 Jan; 29(1):79-88. PubMed ID: 12602495
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An Investigation on the Effect of Polyethylene Oxide Concentration and Particle Size in Modulating Theophylline Release from Tablet Matrices.
    Shojaee S; Emami P; Mahmood A; Rowaiye Y; Dukulay A; Kaialy W; Cumming I; Nokhodchi A
    AAPS PharmSciTech; 2015 Dec; 16(6):1281-9. PubMed ID: 25771738
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of formulation composition on the properties of controlled release tablets prepared by roller compaction.
    Hariharan M; Wowchuk C; Nkansah P; Gupta VK
    Drug Dev Ind Pharm; 2004 Jul; 30(6):565-72. PubMed ID: 15285329
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Application of design of experiments to optimizing novel gastroretentive drug delivery of simvastatin.
    Jagdale S; Kurhe P; Kuchekar B; Chabukswar A
    Curr Drug Deliv; 2013 Oct; 10(5):527-41. PubMed ID: 23607639
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimization of budesonide compression-coated tablets for colonic delivery.
    Yehia SA; Elshafeey AH; Sayed I; Shehata AH
    AAPS PharmSciTech; 2009; 10(1):147-57. PubMed ID: 19199041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preparation and evaluation of an ispaghula based directly compressible matrixing agent for controlled release.
    Lalwani AN; Parikh JR
    Acta Pharm; 2008 Sep; 58(3):309-16. PubMed ID: 19103567
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of tablet formulation and hardness on in vitro release of cephalexin from Eudragit L100 based extended release tablets.
    Saravanan M; Nataraj KS; Ganesh KS
    Biol Pharm Bull; 2002 Apr; 25(4):541-5. PubMed ID: 11995942
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Formulation of fenofibrate liquisolid tablets using central composite design.
    Patel T; Patel LD; Suhagia BN; Soni T; Patel T
    Curr Drug Deliv; 2014; 11(1):11-23. PubMed ID: 24712439
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.